Pathogenesis of Guillain-Barre syndrome

Journal of Neuroimmunology

Volumn 100, Issue 1-2, 1999, Pages 74-97

  Hughes, R A C ^a   Hadden, R D M ^a   Gregson, N A ^a   Smith, K J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; GANGLIOSIDE; GANGLIOSIDE ANTIBODY; GANGLIOSIDE GD 1B; GANGLIOSIDE GM1; GANGLIOSIDE GM2; GANGLIOSIDE GQ 1B; GLYCOSPHINGOLIPID; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; MATRIX METALLOPROTEINASE; MYELIN; MYELIN BASIC PROTEIN; MYELIN PROTEIN; NITRIC OXIDE;

ANTIBODY RESPONSE; CAMPYLOBACTER JEJUNI; CLINICAL FEATURE; CYTOMEGALOVIRUS; CYTOTOXIC T LYMPHOCYTE; DEMYELINATION; GUILLAIN BARRE SYNDROME; HUMAN; INFECTION; MOUSE; NEUROPATHY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; REVIEW; SUBCLAVIAN STEAL SYNDROME; T LYMPHOCYTE;

EID: 0033375608     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(99)00195-2     Document Type: Article

References (268)

1. Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force Research criteria for the diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Neurology. 41:1991;617-618.
2. Adelmann M., Linington C. Molecular mimicry and the autoimmune response to the peripheral nerve myelin PO glycoprotein. Neurochem. Res. 17:1992;887-891.
3. Arasaki K., Kusunoki S., Kudo M., Tamaki M. The pattern of antiganglioside antibody reactivities producing myelinated nerve conduciton block in vitro. J. Neurol. Sci. 161:1998;163-168.
4. Archelos J.J., Previtali S.C., Hartung H.-P. The role of integrins in immune-mediated diseases of the nervous system. Trends Neurosci. 22:1999;30-38.
5. Arnason, B., Soliven, B., 1993. Acute inflammatory demyelinating polyradiculoneuropathy. In: Dyck, P.J., Thomas, P.K., Griffin, J.W., Low, P.A., Poduslo, J.F. (Eds.), Peripheral Neuropathy, 3rd edn. Saunders, Philadelphia, pp. 1437-1497.
6. Asbury A.K., Arnason B.G., Adams R.D. The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis. Medicine. 48:1969;173-215.
7. Aspinall G.O., Fujimoto S., McDonald A.G., Pang H., Kurjanczyk L.A., Penner J.L. Lipopolysaccharides from Campylobacter jejuni associated with Guillain-Barré syndrome patients mimic human gangliosides in structure. Infect. Immun. 62:1994;2122-2125.
8. Ben-Smith A., Gaston J.S.H., Barber P.C., Winer J.B. Isolation and characterisation of T lymphocytes from sural nerve biopsies in patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. J. Neurol. Neurosurg. Psychiatry. 61:1996;362-368.
9. Berciano J., Coria F., Monton F., Calleja J., Figols J., LaFarga M. Axonal form of Guillain-Barré syndrome: evidence for macrophage-associated demyelination. Muscle Nerve. 16:1993;744-751.
10. Berciano J., Figols J., García A., Calle E., Illa I., LaFarga M., Berciano M.T. Fulminant Guillain-Barré syndrome with universal inexcitability of peripheral nerves: a clinicopathological study. Muscle Nerve. 20:1997;846-857.
11. Berlit P., Rakicky J. The Miller Fisher syndrome. Review of the literature. [Review]. J. Clin. Neuro-Ophthalmol. 12:1992;57-63.
12. Blaser M.J., Olivares A., Taylor D.N., Cornblath D.R., McKhann G.M. Campylobacter serology in patients with Chinese paralytic syndrome. Lancet. 338:1991;308-308.
13. Brechenmacher C., Vital C., Deminiere C., Laurentjoye L., Castaing Y., Gbikipi-Penissan G., Cardinaud J.P., Favarel-Garrigues J.-P. Guillain-Barré syndrome: an ultrastructural study of peripheral nerve in 65 patients. Clin. Neuropathol. 6:1987;19-24.
14. Brinkmeier H., Wollinsky K.H., Hulser P.J., Seewald M.J., Mehrkens H., Kornhuber H.H., Rudel R. The acute paralysis in Guillain-Barré syndrome is related to a Na+ channel blocking factor in the cerebrospinal fluid. Eur. J. Physiol. 421:1992;552-557.
15. Brinkmeier H., Wollinsky K.H., Seewald M.J., Hülser P.-J., Mehrkens H.-H., Kornhuber H.H., Rüdel R. Factors in the cerebrospinal fluid of multiple sclerosis patients interfering with voltage-dependent sodium channels. Neurosci. Lett. 156:1993;172-175.
16. Brinkmeier H., Seewald M.J., Wollinsky K.H., Rudel R. On the nature of endogenous antiexcitatory factors in the cerebrospinal fluid of patients with demyelinating neurological disease. Muscle Nerve. 19:1996;54-62.
17. Brown M.J., Rosen J.L., Lisak R.P. Demyelination in vitro by GBS and other human serum. Muscle Nerve. 10:1987;263-271.
18. Buchwald B., Weishaupt A., Toyka K., Dudel J. Pre- and postsynaptic blockade of neuromuscular transmission by Miller-Fisher syndrome IgG at mouse nerve terminals. Eur. J. Neurosci. 10:1998;281-290.
19. Buchwald B., Dudel J., Toyka K.V. Neuromuscular blockade by immunoglobulin G from patients with Miller-Fisher syndrome. Ann. N.Y. Acad. Sci. 841:1998;659-669.
20. Buchwald B., Toyka K.V., Zielasek J., Weishaupt A., Schweiger J., Dudel J. Neuromuscular blockade by IgG antibodies from patients with Guillain-Barré syndrome: a macro-patch-clamp study. Ann. Neurol. 121:1998;1257-1266.
21. Buchwald B., Weishaupt A., Toyka K., Dudel J. Immunoglobulin G from a patient with Miller-Fisher syndrome repidly and reversibly depresses evoked quantal release at the neuromuscular junction of mice. Neurosci. Lett. 201:1995;163-166.
22. Carpenter S. An ultrastructural study of an acute fatal case of the Guillain-Barré syndrome. J. Neurol. Sci. 15:1972;125-140.
23. 1b by cultured neurons: use of rabbit anti-ganglioside sera. J. Neuroimmunol.
24. 1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies. Neurology. 43:1993;1911-1917.
25. Chiba A., Kusunoki S., Obata H., Machinami R., Kanazawa I. Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome. Brain Res. 745:1997;32-36.
26. Chroni E., Hall S.M., Hughes R.A.C. Chronic relapsing axonal neuropathy: a first case report. Ann. Neurol. 37:1995;112-115.
27. Collins S., O'Loughlin E., O'Rourke J., Li Z., Lee A., Howden M. A cytotonic, cholera toxin-like protein produced by Campylobacter jejuni. Comp. Biochem. Physiol. B: Comp. Biochem. 103:1992;299-303.
28. Connolly A.M., Pestronk A., Trotter J.L., Feldman E.L., Cornblath D.R., Olney R.K. High-titer selective serum anti-β-tubulin antibodies in chronic inflammatory demyelinating polyneuropathy. Neurology. 43:1993;557-562.
29. Cook S.D., Dowling P.C. The role of autoantibody and immune complexes in the pathogenesis of Guillain-Barré syndrome. Ann. Neurol. 9:1981;70-79. Suppl.
30. Corbo M., Quattrini A., Latov N., Hays A.P. Localization of GM1 and Gal(β1-3)GalNAc antigenic determinants in peripheral nerve. Neurology. 43:1993;809-814.
31. Cornblath D.R., Griffin D.E., Welch D., Griffin J.W., McArthur J.C. Quantitative analysis of endoneurial T-cells in human sural nerve biopsies. J. Neuroimmunol. 26:1990;113-118.
32. Créange A., Bélec L., Clair B., Raphaël J.C., Gherardi R.K. Circulating tumor necrosis factor (TNF)-α and soluble TNF-α receptors in patients with Guillain-Barré syndrome. J. Neuroimmunol. 68:1996;95-99.
33. Cruz M., Ernerudh J., Olsson T., Hoseberg B., Link H. Occurrence and isotype of antibodies against peripheral nerve myelin in serum from patients with peripheral neuropathy and healthy controls. J. Neurol. Neurosurg. Psychiatry. 51:1988;820-825.
34. Dehaene I., Martin J.J., Geens K., Cras P. Guillain-Barré syndrome with ophthalmoplegia: clinicopathologic study of the central and peripheral nervous system, including the oculomotor nerves. Neurology. 36:1986;851-854.
35. Dowling P.C., Cook S.D. Role of infection in Guillain-Barré syndrome: laboratory confirmation of herpes viruses in 41 cases. Ann. Neurol. 9:1981;44-45. Suppl.
36. Exley A.R., Smith N., Winer J.B. Tumour necrosis factor-a and other cytokines in Guillain-Barré syndrome. J. Neurol. Neurosurg. Psychiatry. 57:1994;1118-1120.
37. Feasby T.E., Hahn A.F., Gilbert J.J. Passive transfer studies in Guillain-Barré polyneuropathy. Neurology. 32:1982;1159-1167.
38. Feasby T.E., Gilbert J.J., Brown W.F., Bolton C.F., Hahn A.F., Koopman W.F., Zochodone D.W. An acute axonal form of Guillain-Barré polyneuropathy. Brain. 109:1986;1115-1126.
39. Feasby T.E., Hahn A.F., Brown W.F., Bolton C.F., Gilbert J.J. Two types of axonal degeneration in acute Guillain-Barré syndrome. J. Neurol. 235:1988;S15.
40. Feasby T.E., Hahn A.F., Brown W.F., Bolton C.F., Gilbert J.J., Koopman W.J. Severe axonal degeneration in acute Guillain-Barré syndrome: evidence of two different mechanisms. J. Neurol. Sci. 116:1993;185-192.
41. Figueras A., Morales-Olivas F.J., Capella D., Palop V., Laporte J.-R. Bovine gangliosides and acute motor polyneuropathy. Br. Med. J. 305:1992;1330-1331.
42. Fisher M. Syndrome of ophthalmoplegia, ataxia and areflexia. New Engl. J. Med. 255:1956;57-65.
43. Frampton G., Winer J.B., Cameron J.S., Hughes R.A.C. Severe Guillain-Barré syndrome: an association with IgA anti-cardiolipin antibody in a series of 92 patients. J. Neuroimmunol. 19:1988;133-139.
44. Fredman P., Vedeler C.A., Nyland H., Aarli J.A., Svennerholm L. Antibodies in sera from patients with inflammatory demyelinating polyradiculoneuropathy react with ganglioside LM1 and sulphatide of peripheral nerve myelin. J. Neurol. 238:1991;75-79.
45. Fross R.D., Daube J. Neuropathy in the Miller-Fisher syndrome: clinical and electrophysiologic findings. Neurology. 37:1987;1493-1498.
46. Gabriel C.M., Hughes R.A.C., Moore S.E., Smith K.J., Walsh F.S. Induction of experimental neuritis with peripheral myelin protein 22. Brain. 121:1998;1895-1902.
47. Gabriel C.M., Gregson N.A., Hughes R.A.C. Antibodies to PMP22 in patients with inflammatory neuropathies. J. Neurol. Neurosurg. Psychiatry. 66:1999;260-261.
48. Geczy C., Raper R., Roberts I.M., Meyer P., Bernard C.C.A. Macrophage procoagulant activity as a measure of cell-mediated immunity to P2 protein of peripheral nerves in the Guillain-Barré Syndrome. J. Neuroimmunol. 9:1985;179-191.
49. Gilburd M., Stein M., Tomer Y., Tanne D., Abramsky O., Chapman Y. Autoantibodies to phospholipids and brain extract in patients with the Guillain-Barré syndrome: cross-reactive or pathogenic? Autoimmunity. 16:1999;23-67.
50. Gorodezky C., Varela B., Castro-Escobar L.E., Chavez-Negrete A., Escobar-Gutierrez A., Martinez-Mata J. HLA-DR antigens in Mexican patients with Guillain-Barré syndrome. J. Neuroimmunol. 4:1983;1-7.
51. Granieri E., Casetta I., Govoni V., Tola M.R., Paolino E., Rocca W.A. Ganglioside therapy and Guillain-Barré syndrome. Neuroepidemiology. 10:1991;161-169.
52. Gregson N.A., Hall S.M. A quantitative analysis of the effects of the intraneural injection of lysophosphatidylcholine. J. Cell Sci. 13:1973;257-277.
53. Gregson N.A., Hammer C.T. Some immunological properties of antisera raised against the trisialoganglioside GT1B. Mol. Immunol. 19:1982;543-550.
54. Gregson N.A., Rees J.H., Hughes R.A.C. Reactivity between IgG anti-GM1 ganglioside antibodies and the lipopolysaccharide fractions of Campylobacter jejuni isolates from patients with Guillain-Barré syndrome (GBS). J. Neuroimmunol. 73:1997;28-36.
55. Griffin J.W., Li C.Y., Ho T.W., Xue P., Macko C., Gao C.Y., Yang C., Tian M., Mishu B., Cornblath D.R., McKhann G.M., Asbury A.K. Guillain-Barré syndrome in northern China. The spectrum of neuropathological changes in clinically defined cases. Brain. 118:1995;577-595.
56. Griffin J.W., Li C.Y., Ho T.W., Tian M., Gao C.Y., Xue P., Mishu B., Cornblath D.R., Macko C., McKhann G.M., Asbury A.K. Pathology of the motor-sensory axonal Guillain-Barré syndrome. Ann. Neurol. 39:1996;17-28.
57. Griffin J.W., Li C.Y., Ho T.W., Xue P., Macko C., Gao C.Y., Yang C., Tian M., Mishu B., Cornblath D.R., McKhann G.M., Asbury A.K. Guillain-Barré syndrome in northern China. The spectrum of neuropathological changes in clinically defined cases - Reply. Brain. 119:1996;677-680.
58. Griffin J.W., Li C.Y., Macko C., Ho T.W., Hsieh S.T., Xue P., Wang F.A., Cornblath D.R., McKhann G.M., Asbury A.K. Early nodal changes in the acute motor axonal neuropathy pattern of the Guillain-Barré syndrome. J. Neurocytol. 25:1996;33-51.
59. Guiloff R.J. Peripheral nerve conduction in Miller Fisher syndrome. J. Neurol. Neurosurg. Psychiatry. 40:1977;801-807.
60. Gupta S.K., Taly A.B., Suresh T.G., Rao S., Nagaraja D. Acute idiopathic axonal neuropathy (AIAN): a clinical and electrophysiological observation. Acta Neurol. Scand. 89:1994;220-224.
61. The Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group, Hadden R.D.M., Cornblath D.R., Hughes R.A.C., Zielasek J., Hartung H.-P., Toyka K.V., Swan A.V. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Ann. Neurol. 44:1998;780-788.
62. Hafer-Macko C., Hsieh S.T., Li C.Y., Ho T.W., Sheikh K., Cornblath D.R., McKhann G.M., Asbury A.K., Griffin J.W. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann. Neurol. 40:1996;635-644.
63. Hafer-Macko C.E., Sheikh K.A., Li C.Y., Ho T.W., Cornblath D.R., McKhann G.M., Asbury A.K., Griffin J.W. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann. Neurol. 39:1996;627-637.
64. Hagensee M.E., Benyunes M., Miller J.A., Spach D.H. Campylobacter jejuni bacteremia and Guillain-Barré syndrome in a patient with GVHD after allogeneic BMT. Bone Marrow Transplant. 13:1994;349-351.
65. Hahn A.F., Feasby T.E., Wilkie L., Lovgren D. Antigalactocerebroside antibody increases demyelination in adoptive transfer experimental allergic neuritis. Muscle Nerve. 16:1993;1174-1180.
66. Hakomori S. Glycosphingolipids in cellular interaction, differentiation and oncogenesis. Ann. Rev. Biochem. 50:1981;733-764.
67. Hall S.M., Gregson N.A. The in vivo and ultrastructural effects of injection of lysophosphatidyl choline into myelinated peripheral nerve fibres. J. Cell Sci. 9:1971;769-789.
68. Hall S.M., Hughes R.A.C., Payan J., Atkinson P.F., McColl I., Gale A. Motor nerve biopsy in severe Guillain-Barré syndrome. Ann. Neurol. 31:1992;441-444.
69. Hao Q., Saida T., Kuroki S., Nishimura M., Nukina M., Obayashi H., Saida K. Antibodies to gangliosides and galactocerebroside in patients with Guillain-Barré syndrome with preceding Campylobacter jejuni and other identified infections. J. Neuroimmunol. 81:1998;116-126.
70. Hao Q., Saida T., Yoshino H., Kuroki S., Nukina M., Saida K. Anti-GalNAc-GD1a antibody-associated Guillain-Barré syndrome with a predominantly distal weakness without cranial nerve impairment and sensory disturbance. Ann. Neurol. 45:1999;758-768.
71. Harrison B.M., Hansen L.A., Pollard J.D., McLeod J.G. Demyelination induced by serum from patients with Guillain-Barré syndrome. Ann. Neurol. 15:1984;163-170.
72. Hartung H.-P., Hughes R.A.C., Taylor W.A., Heininger K., Reiners K., Toyka K.V. T cell activation in Guillain-Barré syndrome and in MS: elevated serum levels of soluble IL-2 receptors. Neurology. 40:1990;215-218.
73. Hartung H.-P., Reiners K., Michels M., Hughes R.A.C., Zielasek J., Enders U., Toyka K.V. Serum levels of soluble E-selectin (ELAM-1) in immune-mediated neuropathies. Neurology. 44:1994;1153-1158.
74. Harvey G.K., Pollard J.D. Peripheral nervous system demyelination from systemic transfer of experimental allergic neuritis serum. J. Neuroimmunol. 41:1992;159-166.
75. 1 IgG or IgM to induce conduction block following intraneural transfer. Muscle Nerve. 18:1995;388-394.
76. Hemachudha T., Griffin D.E., Chen W.W., Johnson R.T. Immunologic studies of rabies vaccination-induced GBS. Neurology. 38:1988;375-378.
77. Hirota N., Kaji R., Bostock H., Shindo K., Kawasaki T., Mizutani K., Oka, Kohara N., Saida T., Kimura J. The physiological effect of anti-GM1 antibodies on saltatory conduction and transmembrane currents in single motor axons. Brain. 120:1997;2159-2169.
78. Ho T.W., Mishu B., Li C.Y., Gao C.Y., Cornblath D.R., Griffin J.W., Asbury A.K., Blaser M.J., McKhann G.M. Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain. 118:1995;597-605.
79. Ho, T.W., Hsieh, S.-T., Nachamkin, I., Willison, H.J., Sheikh, K., Kiehlbauch, J., Flanigan, K., McArthur, J.C., Cornblath, D.R., McKhann, G.M., Griffin, J.W., 1997a. Motor nerve terminal degeneration provides a potential mechanism for rapid recovery in acute motor axonal neuropathy after Campylobacter infection. American Academy of Neurology, 717-724.
80. Ho T.W., Li C.Y., Cornblath D.R., Gao C.Y., Asbury A.K., Griffin J.W., McKhann G.M. Patterns of recovery in the Guillain-Barré syndromes. Neurology. 48:1997;695-700.
81. Ho T.W., Willison H.J., Nachamkin I., Li C.Y., Veitch J., Ung H., Wang G.R., Liu R.C., Cornblath D.R., Asbury A.K., Griffin J.W., McKhann G.M. Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barré syndrome. Ann. Neurol. 45:1999;168-173.
82. Hodgson A.E., McBride B.W., Hudson M.J., Hall G., Leach S.A. Experimental campylobacter infection and diarrhoea in immunodeficient mice. J. Med. Microbiol. 47:1998;799-809.
83. Honavar M., Tharakan J.K.J., Hughes R.A.C., Leibowitz S., Winer J.B. A clinicopathological study of Guillain-Barré syndrome: nine cases and literature review. Brain. 114:1991;1245-1270.
84. Hughes, R.A.C., 1990. Guillain-Barré Syndrome, Heidelberg, Springer-Verlag.
85. Hughes R.A.C., Rees J.H. Clinical and epidemiological features of Guillain-Barré syndrome. J. Infect. Dis. 176:1997;S92-S98. Suppl. 2.
86. Hughes R.A.C., Gray I.A., Gregson N.A., Kadlubowski M., Kennedy M., Leibowitz S., Thompson H. Immune responses to myelin antigens in Guillain-Barré syndrome. J. Neuroimmunol. 6:1984;303-312.
87. Hughes R., Sanders E., Hall S., Atkinson P., Colchester A., Payan J. Subacute idiopathic demyelinating polyradiculoneuropathy. Arch. Neurol. 49:1992;612-616.
88. Hughes R.A.C., Atkinson P., Coates P., Hall S., Leibowitz S. Sural nerve biopsies in Guillain-Barré syndrome: axonal degeneration and macrophage-mediated demyelination and absence of cytomegalovirus genome. Muscle Nerve. 15:1992;568-575.
89. Hughes P.M., Wells G.M.A., Clements J.M., Gearing A.J.H., Redford E.J., Davies M., Smith K.J., Hughes R.A.C., Brown M.C., Miller K.M. Matrix metalloproteinase expression during experimental autoimmune neuritis. Brain. 121:1998;481-494.
90. Hulser P.J., Wietholter H., Wollkinsky K.H. Liquorpheresis eliminates blocking factors from cerebrospinal fluid in polyradiculoneuritis (Guillain-Barré syndrome). Eur. Arch. Psychiatry Clin. Neurosci. 241:1991;69-72.
91. Illa I., Ortiz N., Gallard E., Juarez C., Grau J.M., Dalakas M.C. Acute axonal Guillain-Barré syndrome with IgG antibodies against motor axons following parenteral gangliosides. Ann. Neurol. 38:1995;218-224.
92. Ilyas A.A., Mithen F.A., Chen Z.-W., Cook S.D. Search for antibodies to neutral glycolipids in sera of patients with Guillain-Barré syndrome. J. Neurol. Sci. 102:1991;67-75.
93. Ilyas A.A., Mithen F.A., Dalakas M.C., Wargo M., Chen Z.-W., Bielory L., Cook S.D. Antibodies to sulfated glycolipids in Guillain-Barré syndrome. J. Neurological Sci. 105:1991;108-117.
94. M1 IgA antibodies in Guillain-Barré syndrome. J. Neuroimmunol. 36:1992;69-76.
95. Ilyas A.A., Mithen F.A., Dalakas M.C., Chen Z.-W., Cook S.D. Antibodies to acidic glycolipids in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. J. Neurological Sci. 107:1992;111-121.
96. Ilyas A.A., Cook S.D., Mithen F.A., Taki T., Kasama T., Handa S., Hamasaki H., Singhal B.S., Li S.C., Li Y.T. Antibodies to GT1a ganglioside in patients with Guillain-Barré syndrome. J. Neuroimmunol. 82:1998;160-167.
97. 2 antibodies in Guillain-Barré syndrome with acute cytomegalovirus infection. J. Neuroimmunol. 68:1996;19-26.
98. Izumo S., Linington C., Wekerle H., Meyermann R. Morphological study on EAN mediated by T-cell line specific for bovine P2 protein in Lewis rats. Lab. Invest. 53:1985;209-218.
99. 1b IgG antibodies recognize surface epitopes on Campylobacter jejuni from patients with Miller Fisher syndrome. Ann. Neurol. 37:1995;260-264.
100. Jacobs B.C., van Doorn P.A., Schmitz P.I.M., Tio-Gillen A.P., Herbrink P., Visser L.H., Hooijkaas H., Van der Meché F.G.A. Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome. Ann. Neurol. 40:1996;181-187.
101. Jacobs B.C., Hazenberg M.P., van Doorn P.A., Endtz H.P., Van der Meché F.G.A. Cross-reactive antibodies against gangliosides and Campylobacter jejuni lipopolysaccharides in patients with Guillain-Barré or Miller Fisher syndrome. J. Infect. Dis. 175:1997;729-733.
102. Jacobs B.C., van Doorn P.A., Groeneveld J.H.M., Tio-Gillen A.P., Van der Meche F.G.A. Cytomegalovirus infections and anti-GM2 antibodies in Guillain-Barré syndrome. J. Neurol. Neurosurg. Psychiatry. 62:1997;641-643.
103. Jacobs B.C., Rothbarth P.H., Van der Meché F.G., Herbrink P., Schmitz P.I.M., de Klerk M.A., van Doorn P.A. The spectrum of antecedent infections in Guillain-Barré syndrome: a case control study. Neurology. 51:1998;1110-1115.
104. Jamal G.A., Macleod W.N. Electrophysiologic studies in Miller Fisher syndrome. Neurology. 34:1984;685-688.
105. Kaplan J.E., Katona P., Hurwitz E.S., Schonberger L.B. Guillain-Barré syndrome in the United States, 1979-1980 and 1980-1981. Lack of an association with influenza vaccination. J. Am. Med. Assoc. 248:1982;698-700.
106. Kaplan J.E., Schonberger L.B., Hurwitz E.S., Katona P. Guillain-Barré syndrome in the United States 1978-1981; additional observations from the national surveillance system. Neurology. 33:1983;633-637.
107. Kashihara, K., Shiro, Y., Koga, M., Yuki, N., 1999. IgG anti-GT1a antibodies which do not cross react with GQ1b ganglioside in a pharyngeal-cerevical-brachial variant of Guillain-Barré syndrome. Lancet, 799.
108. Kaslow R.A., Sullivan-Bolyai J.Z., Hafkin B., Schonberger L.B., Kraus L., Moore M.J., Yunis E., Williams R.M. HLA antigens in Guillain-Barré syndrome. Neurology. 34:1984;240-242.
109. Khalili-Shirazi A., Hughes R.A.C., Brostoff S., Linington C., Gregson N. T cell response to myelin proteins in Guillain-Barré syndrome. J. Neurol. Sci. 111:1992;200-203.
110. 2 myelin proteins in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy. J. Neuroimmunol. 46:1993;245-252.
111. Khalili-Shirazi A., Gregson N.A., Hall M.A., Hughes R.A.C., Lanchbury J.S. T Cell Receptor Vβ Gene Usage in Guillain-Barré Syndrome. J. Neurol. Sci. 145:1997;169-176.
112. Khalili-Shirazi A., Gregson N., Londei M., Summers L., Hughes R.A.C. The distribution of CD1 molecules in inflammatory neuropathy. J. Neurol. Sci. 158:1998;154-163.
113. Khalili-Shirazi, A., Gregson, N., Gray, I.A., Rees, J.H., Winer, J.B., Hughes, R.A.C., 1999. Antiganglioside antibodies in Guillain-Barré syndrome following a recent cytomegalovirus infection. J. Neurol. Neurosurg. Psychiatry, In Press.
114. Kikuchi M., Tagawa Y., Iwamoto H., Hoshino H., Yuki N. Bickerstaff's brainstem encephalitis associated with IgG anti-GQ1b antibody subsequent to Mycoplasma pneumoniae infection: Favorable response to immunoadsorption therapy. J. Child Neurol. 12:1997;403-405.
115. Kinnunen E., Junttila O., Haukka J., Hovi T. Nationwide oral poliovirus vaccination campaign and the incidence of Guillain-Barré syndrome. Am. J. Epidemiol. 147:1998;69-73.
116. Koga M., Yuki N., Ariga T., Morimatsu M., Hirata K. Is IgG anti-GT1a antibody associated with pharyngeal-cervical-brachial weakness or oropharyngeal palsy in Guillain-Barré syndrome? J. Neurimmunol. 86:1998;74-79.
117. Koga M., Yuki N., Kashiwase K., Tadokoro K., Juji T., Hirata K. Guillain-Barré and Fisher's syndromes subsequent to Campylobacter jejuni enteritis are associated with HLA-B54 and Cw1 independent of anti-ganglioside antibodies. J. Neurimmunol. 88:1998;62-66.
118. Koga M., Yuki N., Takahashi M., Saito K., Hirata K. Close association of IgA anti-ganglioside antibodies with antecedent Campylobacter jejuni infection in Guillain-Barré and Fisher's syndromes. J. Neuroimmunol. 81:1998;138-143.
119. Koga M., Yuki N., Hirata K. Antiganglioside antibody in patients with Guillain-Barré syndrome who show bulbar palsy as an initial symptom. J. Neurol. Neurosurg. Psychiatry. 66:1999;513-516.
120. Koski C.L. Characterization of complement-fixing antibodies to peripheral nerve myelin in Guillain-Barré syndrome. Ann. Neurol. 27:1990;S44-S47.
121. Koski C.L., Humphrey R., Shin M.L. Anti-peripheral myelin antibodies in patients with demyelinating neuropathy: quantitative and kinetic determination of serum antibodies by complement component and fixation. Proc. Natl. Acad. Sci. USA. 82:1985;905-909.
122. Koski C.L., Gratz E., Sutherland J., Mayer R.F. Clinical correlation with anti-peripheral-nerve myelin antibodies in Guillain-Barré syndrome. Ann. Neurol. 19:1986;573-577.
123. Koski C.L., Sanders M.E., Swoveland P.T., Lawley T.J., Shin M.L., Frank M.M., Joiner K.A. Activation of terminal components of Complement on patients with Guillain-Barré syndrome and other demyelinating neuropathies. J. Clin. Invest. 80:1987;1492-1497.
124. Koski C.L., Chou D.K.H., Jungalwala F.B. Anti-peripheral nerve myelin antibodies in Guillain-Barré Syndrome bind a neutral glycolipid of peripheral myelin and cross-react with Forssman antigen. J. Clin. Invest. 84:1989;280-287.
125. Kuroki S., Saida T., Nukina M., Haruta T., Yoshioka M., Kobayashi Y., Nakanishi H. Campylobacter jejuni strains from patients with Guillain-Barré syndrome belong mostly to Penner serogroup 19 and contain β-N-acetylglucosamine residues. Ann. Neurol. 33:1993;243-247.
126. Kusunoki S., Chiba A., Tai T., Kanazawa I. Localization of GM1 and GD1b antigens in the human peripheral nervous system. Muscle Nerve. 16:1993;752-756.
127. Kusunoki S., Chiba A., Kon K., Ando S., Arisawa K., Tate A., Kanazawa I. N-acetylgalactosaminyl GD1a is a target molecule for serum antibody in Guillain-Barré syndrome. Ann. Neurol. 35:1994;570-576.
128. Kusunoki S., Chiba A., Hitoshi S., Takizawa H., Kanazawa I. Anti-galalactocerebroside antibody in autoimmune neuropathies subsequent to mycoplasma infection. Muscle Nerve. 18:1995;409-413.
129. Kusunoki S., Shimizu J., Chiba R., Ugawa Y., Hitoshi S., Kanazawa I. Experimental sensory neuropathy induced by sensitisation with ganglioside GD1b. Ann. Neurol. 39:1996;324-331.
130. Kusunoki S., Mashiko H., Mochizuki N., Chiba A., Arita M., Hitoshi S., Kanazawa I. Binding of antibodies against GM1 and GD1b in human peripheral nerve. Muscle Nerve. 20:1997;840-845.
131. Kuwabara S., Yuki N., Koga M., Hattori T., Matsuura D., Miyake M., Noda M. IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barré syndrome. Ann. Neurol. 44:1998;202-208.
132. Kuwabara S., Yuki N., Koga M., Hattori T., Matsuura D., Miyake M., Noda M. IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barré syndrome. Ann. Neurol. 44:1998;202-208.
133. Lampert P.W. Mechanism of demyelination in experimental allergic neuritis. Electron microscopic studies. Lab. Invest. 20:1969;127-138.
134. Langmuir A.D., Bregman D.J., Kurland L.T., Nathanson N., Victor M. An epidemiologic and clinical evaluation of GBS reported in association with administration of swine influenza vaccines. Am. J. Epidemiol. 119:1984;841-879.
135. Lasky T., Terracciano G.J., Magder L., Koski C.L., Ballesteros M., Nash D., Clark S., Haber P., Stolley P.D., Schonberger L.B., Chen R.T. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. New Engl. J. Med. 339:1998;1797-1802.
136. Lastovica A.J., Goddard E.A., Argent A.C. Guillain-Barré syndrome in South Africa associated with Campylobacter jejuni. J. Infect. Dis. 176:1997;S139-S143.
137. Latov N., Gross R.B., Kastelman J., Flanagan T., Lamme S., Alkaitis D.A., Olarte M.R., Sherman W.H., Chess L., Penn A.S. Complement fixing antiperipheral nerve myelin antibodies in patients with inflammatory polyneuritis and with polyneuropathy and paraproteinemia. Neurology. 31:1981;1530-1534.
138. Ledeen R.W., Oderfeld-Nowak B., Brosnan C.F., Cervone A. Gangliosides offer partial protection in experimental allergic neuritis. Ann. Neurol. 27:1990;S69-S74. Suppl.
139. Li C.Y., Xue P., Tian W.Q., Liu R.C., Yang C. Experimental Campylobacter jejuni infection in the chicken: an animal model of axonal Guillain-Barré syndrome. J. Neurol. Neurosurg. Psychiatry. 61:1996;279-284.
140. Linington C., Izumo S., Suzuki M., Uyemura M., Meyermann R., Wekerle H. A permanent rat T cell line that mediates experimental allergic neuritis in the rat in vivo. J. Immunol. 133:1984;1946-1950.
141. Linington C., Bradl M., Lassmann H., Brunner C., Vass K. Augmentation of demyelination in rats: acute allergic encephalomyelitis directed against a myelin/oligodendrocyte glycoprotein. Am. J. Pathol. 130:1988;443-454.
142. Linington C., Lassmann H., Ozawa K., Kosin S., Mongan L. Cell adhesion molecules of the immunoglobulin supergene family as tissue-specific autoantigens: induction of experimental allergic neuritis (EAN) by PO protein-specific T cell lines. Eur. J. Immunol. 22:1992;1813-1817.
143. Lisak R.P., Kuchmy D., Armati-Gulson P.J., Brown M.J., Sumner A.J. Serum mediated Schwann cell cytotoxicity in the Guillain-Barré syndrome. Neurology (Cleveland). 34:1984;1240-1243.
144. Lloyd K.O., Gordon C.M., Thampoe I.J., DiBenedetto C. Cell surface accessibility of individual gangliosides in malignant melanoma cells to antibodies is influenced by the total ganglioside composition of the cells. Cancer Res. 52:1992;4948-4953.
145. Low P.A., Schmelzer J., Dyck P.J., Kelly J.J. Endoneurial effects of sera from patients with acute inflammatory polyradiculoneuropathy: electrophysiological studies on normal and demyelinated rat nerves. Neurology. 32:1982;720-724.
146. Low P.A., Schmelzer J.D., Dyck P.J. Results of endoneurial injection of Guillain-Barré serum in Lewis rats. Mayo Clinic Proc. 57:1982;360-364.
147. Ma J.J., Nishimura M., Mine H., Kuroki S., Nukina M., Ohta M., Saji H., Obayashi H., Saida T., Kawakami H., Uchiyama T. HLA and T-cell receptor gene polymorphisms in Guillain-Barré syndrome. Neurology. 51:1998;379-384.
148. Maggio B., Cumar F.A., Caputto R. Configuration and interactions of the polar head group in gangliosides. Biochem. J. 189:1980;435-440.
149. Manfredini E., Nobile-Orazio E., Allaria S., Scarlato G. Anti-alpha- and beta-tubulin IgM antibodies in dysimmune neuropathies. J. Neurol. Sci. 133:1995;79-84.
150. McKhann G.M., Cornblath D.R., Ho T.W., Li C.Y., Bai A.Y., Wu H.S. Clinical and electrophysiological aspects of acute paralytic disease of children and young adults in northern China. Lancet. 338:1991;593-597.
151. McKhann G.M., Cornblath D.R., Griffin J.W., Ho T.W., Li C.Y., Jiang Z., Wu H.S., Zhaori G., Liu Y., Jou L.P., Liu T.C., Gao C.Y., Mao J.Y., Blaser M.J., Mishu B., Asbury A.K. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann. Neurol. 33:1993;333-342.
152. Melnick S.C. 38 cases of the Guillain-Barré syndrome: an immunological study. Br. Med. J. 1:1963;368-373.
153. Mericle R.A., Triggs W.J. Treatment of acute pandysautonomia with intravenous immunoglobulin. J. Neurol. Neurosurg. Psychiatry. 62:1997;529-531.
154. Metral S., Raphael J.C., Hort-Legrand C.I., Elkharrat D. Activité démyélinisante sérique et syndrome de Guillain-Barré: effet favorable des échanges plasmatiques. Rev. Neurol. (Paris). 145:1989;312-319.
155. Milner P., Lovelidge C.A., Taylor W.A., Hughes R.A.C. P0 myelin protein produces experimental allergic neuritis in Lewis rats. J. Neurol. Sci. 79:1987;275-285.
156. Mithen F.A., Ilyas A.A., Birchem R., Cook S.D. Effects of Guillain-Barré sera containing antibodies against glycolipids in cultures of rat Schwann cells and sensory neurons. J. Neurological Sci. 112:1992;223-232.
157. Mizutamari R.K., Wiegandt H., Nores G.A. Characterisation of anti-ganglioside antibodies present in normal human plasma. J. Neuroimmunol. 50:1994;215-220.
158. Monos D.S., Papaioakim M., Ho T.W., Li C.Y., McKhann G.M. Differential distribution of HLA alleles in two forms of Guillain-Barré syndrome. J. Infect. Dis. 176:1997;S180-S182. Suppl. 2.
159. Mori M., Kuwabara S., Miyake M., Dezawa M., Adachi-Usami E., Kuroki H., Noda M., Hattori T. Haemophilus influenzae has a GM1 ganglioside-like structure and elicits Guillain-Barré syndrome. Neurology. 52:1999;1282-1284.
160. Nagai Y., Momoi T., Saito M., Mitsuzawa E., Ohtani S. Ganglioside syndrome, a new autoimmune neurologic disorder, experimentally induced with brain gangliosides. Neurosci. Lett. 2:1976;107-111.
161. Nishimura H., Nukina M., Kuroki S., Obayashi H., Ohta M., Ma J.J., Saida T., Uchiyama T. Characterization of Campylobacter jejuni isolates from patients with Guillain-Barré syndrome. J. Neurol. Sci. 153:1997;91-99. Abstract.
162. Nukada H., Van Rij A.M., Packer S.G.K., McMorran P.D. Pathology of acute and chronic ischaemic neuropathy in atherosclerotic peripheral vascular disease. Brain. 119:1996;1449-1460.
163. Nyholm P.-G., Samuelsson B.E., Breimer M., Pascher I. Conformational analysis of blood group A-active glycosphingolipids using HSEA-calculations. The possible significance of the core oligosaccharide chain for the presentation and recognition of the A-determinant. J. Mol. Recogn. 2:1989;103-113.
164. Nyland H., Aarli J.A. Guillain-Barré syndrome: demonstration of antibodies to peripheral nerve tissue. Acta Neurol. Scand. 58:1978;35-43.
165. O'Leary C.P., Veitch J., Durward W.F., Thomas A.M., Rees J.H., Willison H.J. Acute oropharyngeal palsy is associated with antibodies to GQ1b and GT1a gangliosides. J. Neurol. Neurosurg. Psychiatry. 61:1996;649-651.
166. Ogawa-Goto K., Funamoto N., Abe T., Nagashima K. Different ceramide compositions of gangliosides between human motor and sensory nerves. J. Neurochem. 55:1990;1486-1493.
167. Oomes P., Van der Meche F.G.A., Markus-Silvia L., Meulstee J., Kleyweg R.P. In vivo effects of sera from Guillain-Barré subgroups: an electrophysiological and histological study on rat nerves. Muscle Nerve. 14:1991;1013-1020.
168. Osterman P.O., Vedeler C.A., Ryberg B., Fagius J., Nyland H. Serum antibodies to peripheral nerve tissue in acute Guillain-Barré syndrome in relation to outcome of plasma exchange. J. Neurol. 233:1988;285-289.
169. Paine M.A., Keir G., Plant G.T. Atypical Miller Fisher syndrome with GQ1b antibodies. J. Clin. Neuroscience. 3:1996;268-271.
170. Parkinson J.F., Mitrovic B., Merrill J.E. The role of nitric oxide in multiple sclerosis [see comments] [Review] [151 refs.]. J. Mol. Med. 75:1997;174-186.
171. Patton C.M., Wachsmuth I.K., Evins G.M., Kiehlbauch J.A., Plikaytis B.D., Troup N., Tompkins L., Lior H. Evaluation of 10 methods to distinguish epidemic-associated Campylobacter strains. J. Clin. Microbiol. 29:1991;680-688.
172. 0 protein. J. Neuroimmunol. 54:1994;29-34.
173. Phillips M.S., Stewart S., Anderson J.R. Neuropathological findings in Miller-Fisher syndrome. J. Neurol. Neurosurg. Psychiatry. 47:1984;492-495.
174. Pickett C.L., Pesci E.C., Cottle D.L., Russell G., Erdem A.N., Zeytin H. Prevalence of cytolethal distending toxin production in Campylobacter jejuni and relatedness of Campylobacter sp. cdtB gene. Infect. Immun. 64:1996;2070-2078.
175. Plomp J.J., Molenaar P.C., O'Hanlon G.M., Jacobs B.C., Veitch J., Daha M.R., van Doorn P.A., Van der Meche F.G.A., Vincent A., Morgan B.P., Willison H.J. Miller fisher anti-GQ1b antibodies: alpha-latrotoxin - like effects on motor end plates. Ann. Neurol. 45:1999;189-199.
176. Powell H.C., Hughes R.A.C. Role of non-specific myelin destruction by delayed type hypersensitivity in primary demyelination. J. Neurol. Sci. 74:1987;97. Abstract.
177. Powell H.C., Braheny S.L., Hughes R.A.C., Lampert P.W. Antigen-specific demyelination and significance of the bystander effect in peripheral nerves. Am. J. Pathol. 114:1984;443-453.
178. Previtali S.C., Archelos J.J., Hartung H.-P. Expression of integrins in experimental autoimmune neuritis and Guillain-Barré syndrome. Ann. Neurol. 44:1998;611-621.
179. Prevots D.R., Sutter R.W. Assessment of Guillain-Barré syndrome mortality and morbidity in the United States: implications for acute flaccid paralysis surveillance. J. Infect. Dis. 175:1997;S151-S155. Suppl. 1.
180. Prineas J.W. Acute idiopathic polyneuritis. An electronmicroscope study. Lab. Invest. 26:1972;133-147.
181. Prineas J.W. Pathology of the Guillain-Barré syndrome. Ann. Neurol. 9:1981;6-19. Suppl.
182. Ramos-Alvarez M., Bessudo L., Sabin A.B. Paralytic syndromes associated with noninflammatory cytoplasmic or nuclear neuropathy. J. Am. Med. Assoc. 207:1969;1481-1492.
183. Raschetti R., Maggini M., Popoli P., Caffari B., Da Cas R., Menniti I., Spila-Alegiani S., Traversa G. Gangliosides and Guillain-Barré syndrome. J. Clin. Epidemiol. 48:1995;1399-1405.
184. Redford E.J., Hall S.M., Smith K.J. Demyelination and vascular changes in rat sciatic nerve produced by the intra-neural injection of TNFα Neuropathol. Appl. Neurobiol. 5:1994;505-506.
185. Redford E.J., Hall S.M., Smith K.J. Vascular changes and demyelination induced by the intraneural injection of tumour necrosis factor. Brain. 118:1995;869-878.
186. Redford E.J., Kapoor R., Smith K.J. Nitric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible. Brain. 120:1997;2149-2157.
187. Redford E.J., Smith K.J., Gregson N.A., Davies M., Hughes P., Gearing A.J.H., Miller K., Hughes R.A.C. A combined inhibitor of matrix metalloproteinase activity and tumour necrosis factor alpha processing attenuates experimental autoimune neuritis. Brain. 120:1997;1895-1905.
188. 1 antibodies in Guillain-Barré syndrome and their relationship to Campylobacter jejuni infection. Ann. Neurol. 38:1995;809-816.
189. Rees J.H., Soudain S.E., Gregson N.A., Hughes R.A.C. A prospective case control study to investigate the relationship between Campylobacter jejuni infection and Guillain-Barré syndrome. New Engl. J. Med. 333:1995;1374-1379.
190. Rees J.H., Vaughan R.W., Kondeatis E., Hughes R.A.C. HLA-Class II alleles in Guillain-Barré syndrome and Miller Fisher syndrome and their association with preceding Campylobacter jejuni infection. J. Neuroimmunol. 62:1995;53-57.
191. Roberts M., Willison H., Vincent A., Newsom-Davis J. Serum factor in Miller-Fisher variant of Guillain-Barré syndrome and neurotransmitter release. Lancet. 343:1994;454-455.
192. Roman, G.C., 1995. Tropical neuropathies. In: Hartung, H.-P., (Ed.), Peripheral Neuropathies: Part 1. Baillière Tindall, London, pp. 469-487.
193. Ropper, A.H., 1994. Miller Fisher syndrome and other acute variants of Guillain-Barré syndrome. In: McLeod, J.G. (Ed.), Clinical Neurology: Inflammatory Neuropathies. Baillière-Tindall.
194. Ropper, A.H., 1995. The Guillain-Barré Syndrome - current concepts. New Engl. J. Med.
195. Ropper, A.H., Wijdicks, E.F.M., Truax, B.T., 1991. Guillain-Barré Syndrome, F.A. Davis, Philadelphia.
196. Rostami A.M., Burns J.B., Eccleston P.A., Manning M.C., Lisak R.P., Silberberg D.H. Search for antibodies to galactocerebroside in the serum and CSF in human demyelinating disorders. Ann. Neurol. 22:1987;381-382.
197. Rudnicki S., Vriesendorp F., Koski C.L., Mayer R.F. Electrophysiologic studies in the Guillain-Barré syndrome: effects of plasma exchange and antibody rebound. Muscle Nerve. 15:1992;57-62.
198. Ryberg B. Extra and intrathecal production of antinerve and antibrain antibodies in Guillain-Barré syndrome: evaluation by an antibody index. Neurology. 34:1984;1378-1381.
199. Sack D.A., Lastovica A.J., Chang S.H., Pazzaglia G. Microtiter assay for detecting Campylobacter spp. and Helicobacter pylori with surface gangliosides which bind cholera toxin. J. Clin. Microbiol. 36:1998;2043-2045.
200. Saida T., Saida K., Lisak R.P., Brown M.J., Silberberg D.H., Asbury A.K. In vivo demyelinating activity of sera from patients with Guillain-Barré syndrome. Ann. Neurol. 11:1982;69-75.
201. Salisbury D.M. Association between oral poliovaccine and Guillain-Barré syndrome. Lancet. 351:1998;79-80. Abstract.
202. 3. Infect. Immun. 64:1996;2945-2949.
203. Sanders E.A.C.M., Peters A.C.B., Gratana J.W., Hughes R.A.C. GBS after varicella-zoster infection. Report of two cases. J. Neurol. 234:1987;437-439.
204. Santoro M., Uncini A., Corbo M., Staugaitis S.M., Thomas F.P., Hays A.P., Latov N. Experimental conduction block induced by serum from a patient with anti-GM1 antibodies. Ann. Neurol. 31:1992;385-390.
205. Sawant-Mane S., Clark M.B., Koski C.L. In vitro demyelination by serum antibody from patients with Guillain-Barré syndrome requires terminal complement complexes. Ann. Neurol. 29:1991;397-404.
206. Sawant-Mane S., Estep A. III, Koski C.L. Antibody of patients with Guillain-Barré syndrome mediates complement-dependent cytolysis of rat Schwann cells: susceptibility to cytolysis reflects Schwann cell phenotype. J. Neuroimmunol. 49:1994;145-152.
207. Sáez-Torres I., Diaz-Villoslada P., Martínez-Cáceres E., Ferrer I., Montalban X. Gangliosides do not elicit experimental autoimmune encephalomyelitis in Lewis rats and SJL mice. J. Neuroimmunol. 84:1998;24-29.
208. Schmidt B., Toyka K.V., Kiefer R., Full J., Hartung H.P., Pollard J. Inflammatory infiltrates in sural nerve biopsies in Guillain-Barré syndrome and chronic inflammatory demyelinating neuropathy. Muscle Nerve. 19:1996;474-487.
209. Schönhöfer P.S. Guillain-Barré syndrome and parenteral gangliosides. Lancet. 338:1991;757-757.
210. Sharief M.K., Ingram D.A., Swash M. Circulating tumor necrosis factor-α correlates with electrodiagnostic abnormalities in Guillain-Barré syndrome. Ann. Neurol. 42:1997;68-73.
211. Smith K.J., Hall S.M. Peripheral demyelination and remyelination initiated by the calcium-selective ionophore ionomycin: in vivo observations. J. Neurol. Sci. 83:1988;37-53.
212. Smith K.J., Bostock H., Hall S.M. Saltatory conduction precedes remyelination in axons demyelinated with lysophosphatidylcholine. J. Neurol. Sci. 54:1982;13-31.
213. Smith K.J., Kapoor R., Felts P.A. Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol. 9:1999;69-92.
214. 2-reactive T cells in experimental allergic neuritis. J. Neuroimmunol. 57:1995;77-84.
215. Spies J.M., Westland K.W., Bonner J.G., Pollard J.D. Intraneural activated T cells cause focal breakdown of the blood-nerve barrier. Brain. 118:1995;857-868.
216. Sumner A. Electrophysiological and morphological effects of the injection of Guillain-Barré sera in the sciatic nerve of the rat. Rev. Neurol. (Paris). 138:1982;17-24.
217. Sumner A., Said G., Idy I., Metral S. Demyelinative conduction block produced by intraneural injection of human Guillain-Barré serum into rat sciatic nerve. Neurology. 32:1982;106-106.
218. Tagawa Y., Irie F., Hirabayashi Y., Yuki N. Cholinergic neuron-specific ganglioside GQ1bα a possible target molecule for serum IgM antibodies in some patients with sensory ataxia. J. Neuroimmunol. 75:1997;196-199.
219. Takigawa T., Yasuda H., Kikkawa R., Shigeta Y., Saida T., Kitasato H. Antibodies against GM1 ganglioside affect K+ and Na+ currents in isolated rat myelinated nerve fibers. Ann. Neurol. 37:1995;436-442.
220. Taylor W.A., Hughes R.A.C. T lymphocyte activation antigens in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy. J. Neuroimmunol. 24:1989;33-39.
221. Terryberry J., Sujita M., Shoenfeld Y.et al. Myelin and microbe-specific antibodies in Guillain-Barré syndrome. J. Clin. Lab. Anal. 9:1995;308-319.
222. Thomas F.P., Trojaborg W., Nagy C., Santoro M., Sadiq S.A., Latov N., Hays A.P. Experimental autoimmune neuropathy with anti-GM1 antibodies and immunoglobulin deposits at the nodes of Ranvier. Acta Neuropathol. 82:1991;378-383.
223. Toyka K.V., Heininger K. Humoral factors in peripheral nerve disease. Muscle Nerve. 10:1987;222-232.
224. Tse K.S., Arbesman C.E., Tomasi T.B., Tourville D. Demonstration of antimyelin antibodies by immunofluorescence in Guillain-Barré syndrome. Clin. Exp. Immunol. 8:1971;881-887.
225. Tuttle J., Chen R.T., Rantala H., Cherry J.D., Rhodes P.H., Hadler S. The risk of Guillain-Barré syndrome after tetanus-toxoid-containing vaccines in adults and children in the United States [see comments] [Review] [17 refs.]. Am. J. Public Health. 87:1997;2045-2048.
226. Uncini A., Santoro M., Corbo M., Lugaresi A., Latov N. Conduction abnormalities induced by sera of patients with multifocal motor neuropathy and anti-GM1 antibodies. Muscle Nerve. 16:1993;610-615.
227. Van den Berg L.H., Lankamp C.L.A.M., De Jager A.E.J., Notermans N.C., Sodaar P., Marrink J., De Jong H.J., Bär P.R., Wokke J.H.J. Anti-sulphatide antibodies in peripheral neuropathy. J. Neurol. Neurosurg. Psychiatry. 56:1993;1164-1168.
228. Van den Berg L.H., Oey P.L., Wokke J.H.J., Veldman H., Wieneke G.H., Notermans S.H.W. Features of the Guillain-Barré syndrome in mice following intraperitoneal injection of patient serum. J. Neurol. Sci. 127:1994;103-106.
229. van der Pol W.L., Scheepers R.H.M., Wokke J.H., Capel P.J.A., van der Winkel J.G.J., Van den Berg L.H. Susceptibility to Guillain-Barré syndrome and IgG receptor polymorphisms. J. Neurol. 245:1998;366-367. Abstract.
230. van Doorn P.A., Brand A., Vermeulen M. Clinical significance of antibodies against peripheral nerve tissue in inflammatory polyneuropathy. Neurology. 37:1987;1798-1802.
231. Vedeler C., Nyland H. Plasma exchange in Guillain-Barré syndrome: effect on anti-peripheral nerve myelin antibodies. Acta. Neurol. Scand. 82:1990;147-149.
232. Vedeler C.A., Nyland H., Matre R. Antibodies to peripheral nerve tissue in sera from patients with acute Guillain-Barré syndrome demonstrated by mixed haemagglutination technique. J. Neuroimmunol. 2:1982;209-214.
233. Visser L.H., Van der Meché F.G.A., Meulstee J., Rothbarth P.P., Jacobs B.C., Schmitz P.I.M., van Doorn P.A. Cytomegalovirus infection and Guillain-Barré syndrome: the clinical, electrophysiologic, and prognostic features. Neurology. 47:1996;668-673.
234. Visser L.H., Rothbarth P.Ph., van der Meché Cytomegalovirus infection and Guillain-Barré syndrome. Neurology. 49:1997;1473-1473.
235. Vrethem M., Skogh T., Berlin G., Holmgren H., Ernerudh J. Antibodies to peripheral nerve myelin may occur without clinical neuropathy in healthy persons. J. Neuroimmunol. 32:1991;219-222.
236. Vriesendorp F.J., Mayer R.F., Koski C.L. Kinetics of anti-peripheral nerve myelin antibody in patients with Guillain-Barré syndrome treated and not treated with plasmapheresis. Arch. Neurol. 48:1991;858-861.
237. Vriesendorp F.J., Mishu B., Blaser M.J., Koski C.L. Serum antibodies to GM1, GD1b, peripheral nerve myelin, and Campylobacter jejuni in patients with Guillain-Barré syndrome and controls: correlation and prognosis. Ann. Neurol. 34:1993;130-135.
238. Waksman B.H., Adams R.D. Allergic neuritis: experimental disease of rabbits induced by the injection of peripheral nervous tissue and adjuvants. J. Exp. Med. 102:1955;213-225.
239. Waksman B.H., Adams R.D. A comparative study of EAN in the rabbit, guinea-pig and mouse. J. Neuropathol. Exp. Neurol. 15:1956;293-310.
240. Walsh F.S., Cronin M., Koblar S., Doherty P., Winer J., Leon A., Hughes R.A.C. Association between glycoconjugate antibodies and Campylobacter infection in patients with Guillain-Barré syndrome. J. Neuroimmunol. 34:1991;43-51.
241. Wassenaar T.M. Toxin production by Campylobacter spp. Clin. Microbiol. Rev. 10:1997;466-476.
242. Watson S.L., Westland K., Pollard J.D. An electrophysiological and histological study of trypsin induced demyelination. J. Neurological Sci. 126:1994;116-125.
243. Weerth S., Berger T., Lassman H., Linington C. Encephalitogenic and neurotogenic T cell responses to the meylin-associated glycoprotein (MAG) in the Lewis rat. J. Neuroimmunol. 95:1999;157-164.
244. Willison H.J., Kennedy P.G.E. Gangliosides and bacterial toxins in Guillain-Barré syndrome. J. Neuroimmunol. 46:1993;105-112.
245. Wilmshurst, J.M., Macleod, M.J., Hughes, E., Hughes, R.A.C., 1999a. Acute sensory neuropathy in an adolescent girl. European Journal of Paediatric Neurology.
246. Wilmshurst J.M., Pohl K.R.E., Vaughan R.W., Hughes R.A.C. Familial Guillain-Barré Syndrome. Eur. J. Neurol. 6:1999;499-503.
247. Winer J.B., Briggs D., Welsh K., Hughes R.A.C. HLA antigens in the Guillain-Barré syndrome. J. Neuroimmunol. 18:1988;13-16.
248. Winer J.B., Gray I.A., Gregson N.A., Hughes R.A.C., Leibowitz S., Shepherd P., Taylor W.A., Yewdall V. A prospective study of acute idiopathic neuropathy. III: Immunologic studies. J. Neurol. Neurosurg. Psychiatry. 51:1988;619-625.
249. Winer J.B., Hughes R.A.C., Anderson M.J., Jones D.M., Kangro H., Watkins R.F.P. A prospective study of acute idiopathic neuropathy. II: Antecedent events. J. Neurol. Neurosurg. Psychiatry. 51:1988;613-618.
250. Wirguin I., Briani C., Suturkova-Milosevic L., Fisher T., Della-Latta P., Chalif P., Latov N. Induction of anti-GM1 ganglioside antibodies by Campylobacter jejuni lipopolysaccharides. J. Neuroimmunol. 78:1997;138-142.
251. Wisniewski H.M., Bloom B.R. Primary demyelination as a non-specific consequence of circulating immunocytes in Guillan-Barré syndrome. A cell-mediated immune reaction. J. Exp. Med. 141:1975;346-359.
252. Wisniewski H., Terry R.D., Whitaker J.N., Cook S.D., Dowling P.C. The Landry-Guillain-Barré syndrome. A primary demyelinating disease. Arch. Neurol. 21:1969;269-276.
253. Würz A., Brinkmeier H., Wollinsky K.H., Mehrkens H.-H., Kornhuber H.H., Rüdel R. Cerebrospinal fluid and serum from patients with inflammatory polyradiculoneuropathy have opposite effects on sodium channels. Muscle Nerve. 18:1995;772-781.
254. Young R.R., Asbury A.K., Corbett J.L., Adams R.D. Pure pandysautonomia with recovery - description and discussion of diagnostic criteria. Brain. 98:1975;613-636.
255. Yuki N. Molecular mimicry between gangliosides and lipopolysaccharides of Campylobacter jejuni isolated from patients with Guillain-Barré syndrome and Miller Fisher syndrome. J. Infect. Dis. 176:1997;S150-S153.
256. Yuki N., Tagawa Y. Acute cytomegalovirus infection and IgM anti-GM2 antibody. J. Neurological Sci. 154:1998;14-17.
257. Yuki N., Tsujino Y. Familial Guillain-Barré syndrome subsequent to Campylobacter jejuni enteritis. J. Pediatr. 126:1995;162.
258. Yuki N., Sato S., Fujimoto S., Yamada S., Tsujino Y., Kinoshita A., Itoh T. Serotype of Campylobacter jejuni, HLA, and the Guillain-Barré syndrome. Muscle Nerve. 15:1992;968-969.
259. 1a antibodies. Muscle Nerve. 15:1992;899-903.
260. Yuki N., Taki T., Inagaki F., Kasama T., Takahashi M., Saito K., Handa S., Miyatake T. A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure. J. Exp. Med. 178:1993;1771-1775.
261. 1b ganglioside and lipopolysaccharides of Campylobacter jejuni isolated from patients with Fisher's syndrome. Ann. Neurol. 36:1994;791-793.
262. Yuki N., Tagawa Y., Handa S. Autoantibodies to peripheral nerve glycosphingolipids SPG, SLPG, and SGPG in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. J. Neuroimmunol. 70:1996;1-6.
263. Yuki N., Taki T., Handa S. Antibody to GalNAc-GD1a and GalNAc-GMlb in Guillain-Barré syndrome subsequent to Campylobacter jejuni enteritis. J. Neuroimmunol. 71:1996;155-161.
264. Yuki N., Tagawa Y., Irie F., Hirabayashi Y., Handa S. Close association of Guillain-Barré syndrome with antibodies to minor monosialogangliosides GM1b and GM1α J. Neuroimmunol. 74:1997;30-34.
265. Ziegler D.W., Gardner J.J., Warfield D.T., Walls H.H. Experimental allergic neuritis-live disease in rabbits after infection with influenza vaccines mixed with gangliosides and adjuvants. Infect. Immun. 42:1983;824-830.
266. 2-specific T cell lines. J. Neuroimmunol. 43:1993;103-112.
267. Zou L.-P., Ma D.-H., Levi M., Wahren B., Wei L., Mix E., Van der Meide P.H., Link H., Zhu J. Antigen-specific immunosuppression: nasal tolerance to P0 protein peptides for the prevention and treatment of experimental autoimmune neuritis in Lewis rats. J. Neuroimmunol. 94:1999;109-121.
268. Zweiman B., Rostami A., Lisak R.P., Moskovitz A.R., Pleasure D.E. Immune reactions to P2 protein in human inflammatory demyelinative neuropathies. Neurology. 33:1983;234-237.